Sandoz Finalizes Purchase of Just-Evotec Biologics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: NASDAQ.COM
Acquisition Announcement: Sandoz has completed the acquisition of Just-Evotec Biologics EU SAS, which includes a development and manufacturing site in Toulouse and a license for advanced continuous-manufacturing technology for biosimilars.
Strategic Alignment: The acquisition aligns with Sandoz's biosimilar strategy, enhancing its in-house drug substance development and manufacturing capabilities while improving efficiency and scalability through the new technology.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
